RxDoctor Payments Data

Amanda Woodward

Family · Newnan, GANPI 1467077990

Payments from drug & device makers

$5,858in general payments, 2019–2025

Across 258 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$721
  • Novartis$357
  • Johnson & Johnson$339
  • Pfizer$292
  • Merck$286
  • Bayer$278
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$5,52994%
  • Education$3296%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,858 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$63,214
Medicare patients
249
Services billed
1,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib11$172,210
EliquisApixaban26$28,659
XareltoRivaroxaban15$11,470
Anastrozole65$828
Dexamethasone23$515
ValacyclovirValacyclovir Hcl22$497
Tamoxifen Citrate15$357
Ondansetron OdtOndansetron16$307
Mirtazapine15$225
Prochlorperazine Maleate13$218
Gabapentin11$155
Tramadol Hcl19$155
Doxycycline Hyclate16$150
Letrozole12$149
Tamsulosin Hcl11$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$52$172,21011 claims
PfizerEliquis$292$28,65926 claims
Johnson & JohnsonXarelto$339$11,47015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →